–Eyes on the FDA approval of fruquintinib in Nov
Impairment as always; eyes on Aion’s upmarket
–Solid 2Q23 earnings quality; Eyes on upmarket
Positive profit alert for FY22; eyeing for a good FY23E
Weather short-term headwinds in 2Q24; eyes on 2H24E recovery
Mid-term evaluation of the Global Strategy to Eliminate Yellow Fever Epidemics (EYE) 2017 - 2026 Volume 1: Report - January 2023
Semiconductor:Synopsys eyes on Ansys: a potential software giant in the making
China Technology–Global fabless/IDM 2Q23 wrap: expect continued inventory correction for non-AI players; All eyes on NVDA 3Q23E guidance
Eyes on monetization potential and margin improvement trajectory
–Eye on upcoming launch of Twist of the Fate